Tech Company Financing Transactions
TRACON Pharmaceuticals Funding Round
On 4/1/2011, TRACON Pharmaceuticals raised $14 million in financing from Nextech Invest, Rally Ventures and Arcus Ventures.
Transaction Overview
Company Name
Announced On
4/1/2011
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Undisclosed
Investors
Nextech Invest (Lead Investor) (Myoung-Ok Kwon)
Rally Ventures (Lead Investor) (Kenji Harada)
Proceeds Purpose
Proceeds from the financing will advance the development of the antibody TRC105, an inhibitor of angiogenesis that is being developed in multiple Phase 1b and Phase 2 indications, that are supported by the National Cancer Institute, including ongoing trials in prostate, bladder and liver cancer.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
4350 La Jolla Village Dr. 800
San Diego, CA 92122
USA
San Diego, CA 92122
USA
Phone
Website
Email Address
Overview
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is a biotechnology company developing next-generation targeted therapies for cancer and related diseases. We are addressing unmet needs in this arena with product candidates that focus on cellular targets specifically implicated in cancer growth and angiogenesis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charles Theuer
Vice President
Jennifer Ellis
VP - Operations
Bonne Adams
VP - Product Management
Sharon Real
VP - Regulatory Affairs
Suzy Benedict
Browse more venture capital transactions:
Prev: 4/1/2011: OfficeDrop venture capital transaction
Next: 4/1/2011: Forerun venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs